Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1.

Mark E. Boye(Eli Lilly (United States)), Gregory L. Price(Eli Lilly (United States)), Claire Ainsworth, Katherine Houghton(RTI Health Solutions), Donald E. Stull(IQVIA (United States))
Journal of Clinical Oncology
May 20, 2017
Cited by 3


Related Papers